Why the study?
Does the subclassification and pharmacological heterogeneity of β-blockers impact their optimal selection and clinical advantages in hypertension?
Does the subclassification and pharmacological heterogeneity of β-blockers impact their optimal selection and clinical advantages in hypertension?
This review emphasizes the pharmacological heterogeneity within the β-blocker class and its implications for optimal drug selection in hypertension management.
No takes yet. Share an insight, caveat, or question.
May inform β-blocker subclass selection in hypertension; leaves open prospective outcome trials.
Poirier et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: